Aura Biosciences announces oversubscribed $80 million financing
22/03/2021 Press release AURA BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $80M FINANCING. Proceeds to Support Pivotal Program of AU-011 for the First Line Treatment of Choroidal Melanoma and Expansion of Virus-like Drug Conjugate (VDC) Platform in additional Ocular Oncology Indications and Solid Tumors Lead Investors Matrix Capital Management and Surveyor Capital (a Citadel…